The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection.

BACKGROUND: In the Highly Active Antiretroviral Therapy (HAART) era, the prognosis of children perinatally infected with HIV-1 has significantly improved, so the number of perinatally-infected females entering child-bearing age and experiencing motherhood is increasing.
METHODS: A description of the medical history and pregnancy outcomes of women with perinatal acquired HIV-1 infection enrolled in the Italian Register for HIV infection in Children.
RESULTS: Twenty-three women had 29 pregnancies. They had started an antiretroviral therapy at a median of 7.7 years (interquartile range, IQR 2.3 - 11.4), and had experienced a median of 4 therapeutic regimens (IQR 2-6). Twenty women (87%) had taken zidovudine (AZT) before pregnancy, in 14 cases as a starting monotherapy. In 21 pregnancies a protease inhibitor-based regimen was used. At delivery, the median of CD4+ T lymphocytes was 450/μL (IQR 275-522), and no viral load was detectable in 15 cases (reported in 21 pregnancies). Twenty-eight children were delivered through caesarean section (median gestational age: 38 weeks, IQR 36-38, median birth weight: 2550 grams, IQR 2270 - 3000). Intravenous AZT was administered during delivery in 26 cases. All children received oral AZT (median: 42 days, IQR 31 - 42), with no adverse events reported. No child acquired HIV-1 infection.
CONCLUSIONS: Despite a long history of maternal infection, multiple antiretroviral regimens and, perhaps, the development of drug-resistant viruses, the risk of mother-to-child transmission does not seem to have increased among the second-generation of HIV-1 exposed infants.

Background

The introduction of Highly Active Antiretroviral Therapy (HAART) has significantly improved the quality of life and prognosis of children with perinatally acquired HIV-1 infection in resource-rich countries [1,2]. As a result, an increasing number of these children are entering adolescence and young adulthood, with a consequent proportion of females becoming sexually active and pregnant. These mothers presented with a long history of HIV-1 infection and sometimes AIDS complications. They had a wide exposition to antiretroviral (ART) drugs and to their, primarily metabolic, chronic side effects. They experienced multiple ART regimens, which were often sub-therapeutic until the advent of HAART, with a consequent risk of acquiring drug-resistant viruses.

Therefore, it has since become crucial to define the pregnancy outcome and effectiveness of ART therapy in preventing mother-to-child HIV-1 transmission (MTCT) in this 2nd generation of HIV-1 exposed infants. Reports from Europe [3,4], Puerto Rico [5], India [6], USA [7-10], and Brazil [11] describe favourable maternal and neonatal outcomes, with a MTCT rate varying from 0 to 7.7%, detected in cases of poor adherence to therapy [10].

Here, we describe the clinical aspects of pregnancy in women with perinatally acquired HIV-1 infection enrolled over the years in the Italian Register for HIV Infection in Children.

Methods

The Italian Register for HIV infection in children (ITLR) is a nationwide, multicentre, prospective study set up by the Italian Association of Paediatrics in 1985. At the moment of patient’s enrolment, written informed consent is obtained from the patient’s guardians; data are treated anonymously as each patient is identified by an alphanumerical code. The study was approved by the review boards and ethics committees of each participating institution, as described in detail elsewhere [1,12]. A retrospective analysis of perinatally HIV-1 infected females, enrolled in the ITLR from its institution and who had a child, was carried out. Information included: the women’s demographic and clinical characteristics, such as their mothers’ risk factors for HIV-1 infection, perinatal ART use, HIV-1 related diseases and comorbidities; the number and types of ART regimens both before and during pregnancy; age at delivery, number of CD4+ T-lymphocytes and viral load at delivery, the mode of delivery; infants’ characteristics (gestational age, sex, birth weight, congenital malformations, any other acute or chronic diseases, adverse events for MTCT prophylaxis, HIV-1 infection status). SPSS (version 20.0) software for Windows was used for data management.

Results

Between 2001 and 2012, 29 children were born to 23 women with perinatal HIV-1 infection. One woman had 3 pregnancies and four women had 2 pregnancies each. See Tables  1, 2 and 3 for data concerning mother-child pairs.

Table 1

Characteristics of HIV-1 vertically infected women

N.	Birth order	Risk factors for HIV infection in grandmothers	Year of birth	Age (years) at start of ART therapy	AZT monotherapy	No of regimens experienced	Years of ART therapy (before the first pregnancy)	Clinical and immunological category at last observation	Age (years) at AIDS onset	Age (years) at delivery
Case 1	1st	Drug abuse	1982	14.6	No	4	13.2	A 1		28.4
Case 2	1st	Sexual intercourse with drug abuser, Drug abuse	1982	10.6	Yes	5	7.7	B 3		24.6
	2nd									26.9
Case 3	1st	Risk sexual intercourse	1983	7.7	Yes	6	17.5	B 3		26.1
Case 4	1st	Drug abuse	1983	11.4	Yes	7	7	B 3		23.9
Case 5	1st	Unknown	1983	21.7	No	1	0	B 3		22
	2nd									23.7
	3th									24.7
Case 6	1st	Drug abuse	1984	6.6	Yes	6	9.7	B 2		17
	2nd									18.3
Case 7	1st	Sexual intercourse with drug abuser	1985	3.1	No	2	20.5	N 2		24.3
Case 8	1st	Drug abuse	1985	3	Yes	15	17.7	C 3	11.5	22.4
Case 9	1st	Sexual intercourse with drug abuser, Drug abuse	1986	12.2	No	2	9.5	C 2	13.1	22.2
Case 10	1st	Sexual intercourse with drug abuser	1986	6.6	Yes	6	14.8	C 3	6.6	22.1
Case 11	1st	Unknown	1986	10.2	No	6	11.1	A 3		22
Case 12	1st	Sexual intercourse with drug abuser	1986	10	Yes	3	6.3	A 2		21.1
	2nd									22.2
Case 13	1st	Unknown	1986	13.3	No	1	11	A 1		25
Case 14	1st	Sexual intercourse with drug abuser	1987	2.3	Yes	3	21.6	B 2		24.5
Case 15	1st	Unknown	1988	14.4	No	2	10.3	B 1		22.6
Case 16	1st	Unknown	1988	1.9	Yes	2	6.2	A 2		19.2
Case 17	1st	Sexual intercourse with drug abuser	1989	1.8	Yes	5	18	A 1		20.3
Case 18	1st	Sexual intercourse with drug abuser, Drug abuse	1990	1.7	Yes	5	14.4	B 2		20.1
Case 19	1st	Drug abuse	1990	5.4	Yes	8	13.9	B 3		20
Case 20	1st	Unknown	1990	8.6	No	4	11.6	A 3		20.8
	2nd									21.7
Case 21	1st	Sexual intercourse with drug abuser	1991	1.2	Yes	3	17.3	B 1		19.3
Case 22	1st	Drug abuse	1991	0.6	Yes	7	19.2	C 3	0.2	20.4
Case 23	1st	Sexual intercourse with drug abuser, Drug abuse	1991	8.2	No	2	9.9	A 2		20

Legend. ART = antiretroviral; AZT = zidovudine.

Table 2

Pregnancy features

N.	Birth order	ART therapy at conception	ART therapy interruption at first trimester	ART regimen during pregnancy	Gestational week at start	Gestational week at end	CD4+ at delivery	VL at delivery	AZT intrapartum	Type of delivery
Case 1	1st	No	No	AZT + 3TC + ATV/rtv	5	37	525	Undetectable	Yes	EC
Case 2	1st	Yes	Yes (from 5th to 12th week)	DDI + 3TC + NVP	1	4	480	157	Yes	EC
				AZT + 3TC + NVP	13	38
	2nd	Yes	No	FTC + TDF + FPV/rtv	1	38	520	Undetectable	Yes	EC
Case 3	1st	Yes	No	FTC + TDF + ATV/rtv	1	38	125	Undetectable	Yes	EC
Case 4	1st	No	No	No			Unknown	Unknown	Yes	EC
Case 5	1st	No	No	AZT + 3TC + LPV/rtv	23	34	307	Unknown	Yes	EC
	2nd	Yes	No	AZT + 3TC + LPV/rtv	1	37	480	15332	Yes	EC
	3th	Yes	No	AZT + 3TC + LPV/rtv	1	Unknown	Unknown	Unknown	Yes	EC
Case 6	1st	No	No	AZT + 3TC + NVP	6	36	Unknown	Unknown	No	EC
	2nd	No	No	AZT + 3TC + NVP	6	40	Unknown	Unknown	No	EC
Case 7	1st	Yes	No	ABC + 3TC + ATV	1	34	323	Undetectable	Yes	EC
				ABC + 3TC + ATV/rtv	35	38
Case 8	1st	Yes	No	FTC + TDF + DRV/rtv	1	38	450	Undetectable	Yes	EC
Case 9	1st	Yes	No	ABC + DDI + LPV/rtv	1	16	312	7653	Yes	EC
				AZT + 3TC + LPV/rtv	17	36
Case 10	1st	Yes	Yes (from 6th to 12th week)	FTC + TDF + EFV	1	5	240	Undetectable	Yes	EC
				AZT + 3TC + LPV/rtv	13	38
Case 11	1st	Unknown	No	ABC + TDF + LPV/rtv	Unknown	39	Unknown	Undetectable	Yes	EC
Case 12	1st	No	No	No			Unknown	Unknown	Yes	UC
	2nd	Yes	No	AZT + 3TC + LPV/rtv	1	38	95	Unknown	Yes	EC
Case 13	1st	Yes	No	FTC + NVP	1	39	673	Undetectable	Yes	EC
Case 14	1st	Yes	No	AZT + 3TC + ABC	1	35	564	Undetectable	Yes	EC
Case 15	1st	Yes	No	FTC + TDF + DRV/rtv	1	37	501	Undetectable	Yes	EC
Case 16	1st	No	No	FTC + TDF + ATV/rtv	16	36	522	Undetectable	Yes	EC
Case 17	1st	No	No	FTC + TDF + ATV	13	37	770	Undetectable	Yes	EC
Case 18	1st	Yes	No	3TC	1	28	440	13099	Yes	LC
				FTC + TDF + DRV/rtv	29	36
Case 19	1st	No	No	FTC + TDF + ATV/rtv	6	38	501	Undetectable	Yes	EC
Case 20	1st	No	No	FTC + TDF + DRV/rtv + RAL	38	40	200	Undetectable	Yes	EC
	2nd	Unknown	Unknown	Unknown			99	Unknown	Unknown	Unknown
Case 21	1st	Yes	No	FTC + TDF + ATV/rtv	1	38	776	615	Yes	EC
Case 22	1st	Yes	No	AZT + DDI + LPV/rtv	1	35	435	Undetectable	Yes	EC
Case 23	1st	Yes	Yes (from 3rd to 9th week)	FTC + TDF + LPV/rtv	1	3	275	20000	Yes	EC
				FTC + TDF + LPV/rtv	10	38

Legend. VL: viral load (copies/ml); AZT: zidovudine; 3TC: lamivudine; ABC: abacavir; FTC: emtricitabine; TDF: tenofovir; DDI: didanosine; NVP: nevirapine; LPV: lopinavir; ATV: atazanavir; FPV: fosamprenavir; DRV: darunavir; rtv: ritonavir booster; RAL: raltegravir; EC = elective caesarean section; UC = unspecified caesarean section; LC = caesarean section after labour.

Table 3

HIV-1 exposed children features

N.	Birth order	Year of birth	Gender	Gestational age (weeks)	Weight at birth (grams)		ART prophylaxis	Duration of postnatal ART prophylaxis (days)	HIV-1 status	Other pathological conditions
Case 1	1st	2010	M	37	2590		AZT	42	SR
Case 2	1st	2007	F	38	2550		AZT	45	SR
	2nd	2009	M	38	3240		AZT	19	SR
Case 3	1st	2009	F	38	3100		AZT	28	SR
Case 4	1st	2007	F	38	2920		AZT	36	SR
Case 5	1st	2005	F	34	1975		AZT	42	SR
	2nd	2007	F	37	1960	SGA	AZT	42	SR	HCV infection
	3th	2008	F	Unknown	Unknown		AZT	28	SR
Case 6	1st	2001	F	36	1880	SGA	AZT	44	SR
	2nd	2002	F	40	3080		AZT	42	SR
Case 7	1st	2009	M	38	2530		AZT	42	SR
Case 8	1st	2008	F	38	2450		AZT	43	SR
Case 9	1st	2008	F	36	2520		AZT	42	SR
Case 10	1st	2008	M	38	3250		AZT	31	SR
Case 11	1st	2008	F	39	2770		AZT	41	SR
Case 12	1st	2007	M	35	2270		AZT + 3TC + NVP	31	SR
	2nd	2008	M	38	3000		AZT + 3TC + NVP	42	SR
Case 13	1st	2011	M	39	3100		AZT	41	SR
Case 14	1st	2011	F	35	1190	SGA	AZT	18	SR
Case 15	1st	2011	M	37	3190		AZT	42	SR
Case 16	1st	2008	F	36	2760		AZT	42	SR
Case 17	1st	2009	M	37	2520		AZT	29	SR	Cryptorchidism
Case 18	1st	2010	M	36	2180		AZT	42	SR
Case 19	1st	2010	F	38	2500		AZT	14	SR
Case 20	1st	2011	F	40	2380	SGA	AZT	45	SR
	2nd	2012	F	Unknown	Unknown		Unknown	Unknown	SR
Case 21	1st	2010	F	38	2750		AZT	42	SR
Case 22	1st	2012	M	35	2160		AZT	42	SR
Case 23	1st	2011	M	38	2690		AZT	33	SR

Legend. M = male; F = female; AZT = zidovudine; 3TC = lamivudine; NVP = nevirapine; SR = seroreverter; SGA= small for gestational age.

The median maternal age at first delivery was 22 years (interquartile range (IQR) 20.1-24.3); the oldest mother was born in 1982, the youngest in 1991. No infected mother was perinatally exposed to antiretroviral drugs, as ART prophylaxis was not used at that time. The grandmothers’ risk factors for HIV-1 infection were known for 17 women: 11 had had high risk sexual intercourse and 6 had been IV drug users. All but one woman had ART therapy during childhood or adolescence. The median age at the start of ART therapy was 7.7 years (IQR 2.3-11.4). The median number of regimens for each woman was 4 (IQR 2–6). Twenty (87%) women were given zidovudine (AZT), in 14 cases as a starting monotherapy for a median period of 4.4 years (IQR 2.0-5.2); 12/14 patients were later shifted to a dual therapy containing AZT (median period 2.4 years, IQR 1.0-3.4). All but 2 women received HAART before pregnancy, with a combination of 3 or more drugs, containing at least one protease-inhibitor (PI) in 16 cases. The median time of the mothers’ exposure to ART drugs before their first pregnancy was 11.6 years (IQR 9.5-17.5). Four women developed an AIDS defining condition (at a median age of 9.0 years, IQR 1.8-12.7); 10 women were classified, according to the CDC paediatric classification, in clinical category B, 8 in category A, 1 in category N. As far as the immunological status is concerned, 5 were in category 1, 8 in category 2, and 10 in category 3.

Ten mothers did not have any ART therapy at the time of conception; of the ten, 2 continued without therapy throughout their pregnancy, 4 started ART therapy in the first trimester and 4 after the 12th week of gestation, including one woman who started a rescue therapy including the integrase inhibitor raltegravir at the 38th week of gestation. In the other pregnancies, the women were already undergoing ART treatment at conception, and 3 of them discontinued therapy in the first trimester (see Table  2). In one case, efavirenz (EFV) was continued during the first 5 weeks of gestation, with a switch to a lopinavir/ritonavir containing combination after the 12th week. A PI-based regimen was used in a total of 21 pregnancies. No complications related to pregnancy were noticed. There was a median of 450/μL (IQR 275–522)CD4+ T lymphocytes at the last check before delivery (reported in 23 of the 29 pregnancies); all women with a previous AIDS-defining condition had > 200 CD4+/μL. The viral load at delivery (reported in 21 pregnancies) was undetectable in 15 cases. Intravenous AZT was administered during 26 (89.6%) deliveries. Twenty-eight children were born through caesarean section, which was elective in 26 cases. No neonatal complications for children at birth were reported; 17 (58.6%) were females; their median gestational age was 38 weeks (IQR 36–38) and the median birth weight was 2550 grams (IQR 2270–3000). Eight were preterm (<37 weeks of gestation), and 4 were small for the gestational age (SGA) (Table  3) [13]. No infant was breastfed. Twenty-six infants received oral AZT as MTCT prophylaxis; 2 brothers received a combined regimen (AZT + 3TC + NVP single dose): the first child because of lack of maternal ART therapy during pregnancy, the second one because of severe maternal immunosuppression (CD4+ T-lymphocytes at labour: 95 cell/ μL). Neonatal ART prophylaxis was administered for a median period of 42 days (IQR 31–42) with no major adverse events.

No child acquired HIV-1 infection. One patient was HCV infected and one presented cryptorchidism. The median age at the last check was 3 years (IQR 1.3-4.3), with nine children followed over 4 years of age.

Discussion

There are few studies exploring the pregnancy outcome in HIV-1 perinatally-infected women. Despite the limited number of pregnancies enrolled and limited amount of available data, ours is one of the largest cohorts with detailed information on the entire maternal history.

The results are reassuring, since none of the 29 exposed infants acquired the infection. Indeed, of the 134 children born to HIV-1 perinatally-infected mothers described in this and other studies [3-11], only 2 acquired the infection, for a total MTCT rate of 1.5%, comparable to that observed in the first-generation of exposed infants with the adoption of the same preventive measures, such as ART therapy during pregnancy, elective caesarean section, ART prophylaxis in the child, and bottle-feeding [12,14,15].

Among 601 women with perinatally acquired HIV-1 infection enrolled in the ITLR, 383 are alive and over 16 years old at the last check. Thus, the 23 described in this case-series represent 6% of those with a similar child-bearing age. It is worth noting that 5 had more than one child. In spite of the prolonged history of HIV-1 infection and of targeted therapies, the good quality of life and a longer life expectancy presumably allowed these women to live motherhood with fewer distressing concerns. The low probability of HIV-1 transmission to the offspring is an additional important factor supporting such women having children. We have no documentation about the possible birth control methods adopted by these women, or whether these pregnancies were planned. However, the median age of our parturients was rather lower than the 32.3 years observed in the general Italian population [16]. This low median age at delivery is consistent with other reports [3,5,6,10], and, perhaps, mirrors the fear that the chronic disease could deprive them of the special female role of motherhood. This growing desire of motherhood among seropositive women clearly emerges from our Register, where the number of HIV-1 perinatally-exposed children is around 350–400 per year, with an increasing multiparity rate, reaching 25% in recent years (data not shown).

In this scenario, the management of HIV-1 perinatally-infected pregnant women and their children will be an important challenge for clinicians in the near future. A crucial aspect will be the choice of the best ART regimen to prevent MTCT. None of our mothers was perinatally exposed to ART drugs, as they were born before the ACTG 076 protocol [17,18]. However, the majority received ART therapy during childhood and experienced several sub-therapeutic regimens. Although resistance data were not available, these conditions are well known to favour the development of drug resistant viruses, with a consequent possible higher risk of MTCT, a phenomenon that fortunately does not emerge from the available data. As far as AZT is concerned, it is worth noting that over half of our mothers started AZT as a monotherapy during childhood, then shifted to a dual therapy including AZT, continuing with such combinations for several years. Six of these 14 women continued to receive AZT also during pregnancy, as did all their children as a prophylaxis, apparently with success, since the majority of the mothers had undetectable viral loads at delivery and no child acquired the infection. This casts doubts on the suggested exclusion of AZT during pregnancy if there had been a prolonged monotherapy during childhood [10]. Indeed, in a recent case series the role of intrapartum intravenous AZT for the prevention of MTCT in women with virological failure has been stressed [19]. AZT may be effective in the prevention of MTCT through other mechanisms besides its direct antiviral effect [18,20].

The possible impact of a prolonged ART therapy on maternal and child health is a further important aspect. Even in this context, our results are reassuring. No congenital abnormalities were noticed, including the child exposed to EFV in the first 5 weeks of gestation [21,22]. Since maternal and neonatal complications due to ART drugs do not seem to be higher in perinatally-infected women, indications should not differ from those commonly recommended in seropositive mothers, for instance HAART should start as soon as possible [15], while stopping ART during pregnancy should be discouraged [12]. In fact, fearing a possible teratogenicity, 3 women discontinued ART treatment during the first trimester of pregnancy and their viral load was detectable at delivery. On the other hand, the experience of several therapeutic regimens during childhood and adolescence will presumably lead to the use of new antiretroviral drugs during pregnancy, such as integrase inhibitors, the impact of which on pregnant women and their foetuses still needs to be elucidated.

Conclusions

The outcome of second-generation HIV-1 exposed infants seems favourable. In spite of a long course of maternal infection, multiple ART regimens, and a possible development of drug-resistant viral strains, MTCT continues to be efficiently controlled by the commonly adopted preventive strategies, even though an adequate surveillance of pregnancy among this unique population is highly recommended.

Competing interests

The Italian Register for HIV Infection in Children was funded by the Istituto Superiore di Sanità, Rome, Italy, and the Paediatric European Network for Treatment of AIDS (PENTA) Foundation, Padua, Italy. The authors declare that they have no competing interests.

Authors’ contributions

All Authors and Co-Authors contributed equally to the study design, acquisition of women and children information and interpretation of data. CC, CG and PAT drafted the manuscript, while MdM, LG, EC, CG, WB, OG, SE, SB critically revised it for its intellectual content. All Authors and Co-Authors accepted the final version of the manuscript.

Authors’ information

Co-Authors: Giacomo Faldella (Bologna), Raffaele Badolato, Chiara Monfredini (Brescia), Cristina Gotta (Genoa), Vania Giacomet (Milan), Monica Cellini (Modena), Osvalda Rampon (Padua), Maura Agnese (Naples), Piero Valentini (Rome), Carlo Scolfaro, Silvia Garazzino (Turin), Antonio Mazza (Trento).

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/14/277/prepub